Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis
| Autor: | A. Potts Bleakman, Russel Burge, P.-D. Ghislain, Joseph F. Merola, Alan Brnabic, E. Riedl, J.N. Dauendorffer |
|---|---|
| Přispěvatelé: | UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de dermatologie |
| Rok vydání: | 2019 |
| Předmět: |
Adult
medicine.medical_specialty Short Report Pain Subgroup analysis Dermatology Placebo Antibodies Monoclonal Humanized Severity of Illness Index 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Double-Blind Method Psoriasis medicine Humans In patient Sex organ Genitalia Reproductive health Body surface area business.industry medicine.disease Ixekizumab Infectious Diseases Treatment Outcome 030220 oncology & carcinogenesis Dermatologic Agents Sexual Health business |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology Journal of the European Academy of Dermatology and Venereology, Vol. 34, no. 6, p. 1257-1262 (2020) |
| ISSN: | 1468-3083 0271-8898 |
| Popis: | Background Epithelial surface disruption in genital psoriatic lesions may manifest as erosions, fissures and/or ulcers, causing pain and significantly impacting a patient's sexual health. Objective To evaluate the impact of erosions, fissures and/or ulcers in genital psoriatic lesions on pain and sexual activity in patients with moderate‐to‐severe genital psoriasis (GenPs) and treatment responses to ixekizumab vs. placebo until Week 12. Methods This post hoc subgroup analysis of patients presenting with and without erosions, fissures and/or ulcers in genital lesions from a phase IIIb multicentre, randomized, double‐blind, placebo‐controlled study (IXORA‐Q; NCT02718898) in 149 adults with moderate‐to‐severe GenPs treated with subcutaneous ixekizumab (80 mg every 2 weeks; n = 75) or placebo (n = 74) evaluated outcomes for clinician‐rated GenPs severity (static Physician's Global Assessment of Genitalia; sPGA‐G) and patient‐reported genital pain and itch (Genital Psoriasis Symptoms Scale; GPSS) and sexual health (Genital Psoriasis Sexual Frequency Questionnaire; GenPs‐SFQ). Results At baseline, 38% (n = 57) of patients presented with genital erosions, fissures and/or ulcers independent of overall body surface area involvement ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text